1. Home
  2. USAU vs CGEN Comparison

USAU vs CGEN Comparison

Compare USAU & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Gold Corp.

USAU

U.S. Gold Corp.

N/A

Current Price

$8.40

Market Cap

242.1M

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

N/A

Current Price

$1.88

Market Cap

201.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USAU
CGEN
Founded
2014
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.1M
201.8M
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
USAU
CGEN
Price
$8.40
$1.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
★ $26.50
$4.80
AVG Volume (30 Days)
153.1K
★ 193.0K
Earning Date
12-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.11
N/A
EPS
N/A
★ N/A
Revenue
★ $17,402,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$55.33
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$9.55
$1.43
52 Week High
$23.72
$3.24

Technical Indicators

Market Signals
Indicator
USAU
CGEN
Relative Strength Index (RSI) 27.43 37.41
Support Level N/A $1.87
Resistance Level $16.65 $2.18
Average True Range (ATR) 0.69 0.09
MACD -0.12 0.00
Stochastic Oscillator 1.26 12.87

Price Performance

Historical Comparison
USAU
CGEN

About USAU U.S. Gold Corp.

U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: